Biotech News

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Praxis Precision Medicines (PRAX)Praxis Precision MedicinesEarnings

FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies (DEEs) expected in the

Related news

Praxis Precision Medicines

Precision Neuroscience Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies. Ulixacaltamide Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential...

Recent company news

Stock data

Close
310.90 USD
Market cap
7.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States